
Home | Harrow, Inc.
Oct 6, 2025 · Harrow is redefining the standard of care in eyecare with a portfolio of trusted, high-value pharmaceutical solutions that deliver proven safety, efficacy, and affordability.
About | Harrow, Inc.
Harrow, a leading provider of ophthalmic disease management solutions in North America, was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance …
Harrow Launches VEVYE® Access for All
Mar 17, 2025 · Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical …
Careers | Harrow, Inc.
At Harrow, our values aren’t just guiding words—they shape how we grow, innovate, and work together. Humility, ownership, preparedness, and entrepreneurship create the foundation for a culture where …
0001493152-25-012840 | 8-K | iXBRL Viewer | Harrow INC
Harrow INC SEC filing: Form 8-K iXBRL on 09/09/2025 (0001493152-25-012840).
Leadership | Harrow, Inc.
Prior to joining Harrow, he was Founder and Chief Executive Officer of LVMA Consulting, advising emerging biotech companies and top 10 global pharmaceutical organizations on commercial …
www.harrow.com
www.harrow.com
Events | Harrow, Inc.
Aug 12, 2025 · Harrow, Inc. Investor & Analyst Day Presentation 6.8 MB August 13, 2025 | 1:00 PM EDT H.C. Wainwright’s 5th Annual Ophthalmology Conference - Panel discussion on Novel …
- [XLS]
www.harrow.com
harrow health inc-2 harrow health inc-1 harrow health inc Harrow Health INC 2,145,767 shares of common stock available for award under the Company’s 2017 Incentive Stock and Awards Plan (the …
- [XLS]
www.harrow.com
Exhibits Press Release issued by Harrow, Inc. on August 11, 2025 Letter to Stockholders by Harrow, Inc. dated August 11, 2025 Harrow Corporate Presentation dated August 2025 Cover Page …